NCT05647512View on ClinicalTrials.gov

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 18, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 30, 2025

Conditions
Relapsed or Refractory Multiple MyelomaOther Plasma Cell Diseases
Interventions
DRUG

LM-305

Administered intravenously

DRUG

Dexamethasone

Administered orally

Sponsors
All Listed Sponsors
lead

LaNova Medicines Limited

INDUSTRY